Targeting FSH for osteoporosis, obesity, and Alzheimer's disease.

Authors

• Funda Korkmaz
• Judit Gimenez-Roig
• Farhath Sultana
• Victoria Laurencin
• Fasilet Sen
• Liam Cullen
• Steven Sims
• Anusha Pallapati
• Satish Rojekar
• Guzel Burganova
• Clifford J. Rosen, MaineHealth Institute for Research, Scarborough, ME.Follow
• Tony Yuen
• Se-Min Kim
• Mone Zaidi

Document Type

Article

Publication Date

11-2025

Institution/Department

Center for Molecular Medicine

Journal Title

Trends in molecular medicine

MeSH Headings

Humans, Alzheimer Disease, Animals, Obesity, Osteoporosis, Follicle Stimulating Hormone

Abstract

Follicle-stimulating hormone (FSH), traditionally known for regulating gonadal development, maturation, and estrogen secretion, has now been implicated in regulating fat and bone metabolism and cognition. Preclinical evidence from genetic and pharmacological studies in rodent models, combined with human data from population-based observations, genetic studies, and a limited number of interventional trials, supports the notion of independent effects of FSH on the skeleton, fat, and brain. This evolving understanding of the nonreproductive roles of FSH presents potential therapeutic opportunities to mitigate age-related health challenges, which include osteoporosis, obesity, cardiovascular risk, and dementia. This review summarizes the current knowledge on the interplay between pituitary-derived FSH and peripheral and central tissues, as well as recent progress in therapeutic development.

ISSN

1471-499X

First Page

1021

Last Page

1031

Recommended Citation

Korkmaz, Funda; Gimenez-Roig, Judit; Sultana, Farhath; Laurencin, Victoria; Sen, Fasilet; Cullen, Liam; Sims, Steven; Pallapati, Anusha; Rojekar, Satish; Burganova, Guzel; Rosen, Clifford J.; Yuen, Tony; Kim, Se-Min; and Zaidi, Mone, "Targeting FSH for osteoporosis, obesity, and Alzheimer's disease." (2025). MaineHealth Maine Medical Center. 4420.
https://knowledgeconnection.mainehealth.org/mmc/4420